

Washington Vaccine Association Vaccine Committee Meeting November 3, 2016; 12:30-1:30 p.m. PDT

I. Attendance. Participating in all or part of the meeting in person by telephone (T) were the following individuals:

Others

Committee Members
Ed Marcuse, MD, Chairman
Rachel Wood, MD
Cathy Falanga, Aetna
John Dunn, MD
Michele Roberts, Department of Health
Rachel Wood, MD (T)
Jeffrey Gombosky (T)

Sasha DeLeon, Department of Health Dennis Kirkpatrick, President, WPAS James Flood, Crowell & Moring Scott Douglas, Crowell & Moring Mary Kay O'Neill, MD, Mercer Consulting Kristin Peterson, Esq., Department of Health

<u>KidsVax</u>[®]
Julia Walter, M.A., Esq., Executive Director Ashley Kittrell, Communications Coordinator

II. Minutes

5

6 7

8

9

10

11 12

13

14

Welcome & Introductions

At 12:30 p.m., a quorum having been established, Chairman Ed Marcuse called the meeting to order. Julia Walter informed the Committee that the meeting is recorded for the benefit of the secretary and will be deleted following the approval of the minutes. Committee members introduced themselves, and Chairman Marcuse asked Sasha DeLeon to proceed with the Department of Health (DOH) updates.

Department of Health Updates

Ms. DeLeon, the DOH Vaccine Assurance Unit Supervisor updated the Committee on several 15 items including flu allocation and ordering, the Advisory Committee on Immunization Practice's 16 (ACIP) recommendation of HPV Gardasil 9 (HPV9), vaccine choice, and Meningococcal B. In 17 preparation for the 2016/17 flu season, approximately 686,000 doses have been pre-booked. 18 Because Flumist is no longer recommended by the ACIP, the stock has been replaced with Fluzone 19 MDV and FluLaval MDV. As of November 1st, approximately 87% allocation to the state is 20 available for ordering, and of the 686,000 doses pre-booked, 345,920 doses have been ordered and 21 22 approximately 247,510 doses remain. Chairman Marcuse asked Ms. DeLeon to clarify the difference between vaccine allocation and ordering. Ms. DeLeon explained that the number of 23 doses each local department of health estimates that it will need is written as an allocation and the 24 DOH reserves the estimated amount. 25

1 Regarding allocation issues, Ms. DeLeon noted that initially, large organizations that cover

- 2 different counties receive the same amount of vaccines, which is sent in either prefilled syringes
- 3 or vials. This year, approximately 70% received prefilled syringes and 30% vials; however, the
- 4 delay of prefilled syringes, the vials have had to replace the prefilled syringes. Michele Roberts
- 5 added that the CDC did not inform the DOH that when it replaced Flumist, some manufacturers
- 6 had to make new vaccine. Ms. DeLeon also noted that there has been an increased demand for pre-
- 7 filled syringes by parents and naturopathic doctors looking for a preservative-free option. There is
- 8 currently no known demand for cell-based and recombinant flu vaccines as these are usually used
- 9 for patients with severe egg allergies. Discussion ensued regarding the demand for preservative-
- 10 free flu vaccine and its possible effect on Flumist.

11

- Ms. DeLeon continued to the discussion of HPV9, noting that the FDA recently approved HPV9
- as a 2-dose series for adolescents between 9 and 14 years old. ACIP believes that the reduction
- 14 from three to two shots will help facilitate series initiation and completion, as well as reduce office
- visits. Children younger than 9 who receive the series will still need to receive the three doses.
- 16 Chairman Marcuse noted that this should result in savings for the WVA. Ms. Roberts replied that
- 17 DOH will have to conduct an analysis to verify and will include it in the budget updates.

18

- 19 Ms. DeLeon continued with the review of the vaccine choice enrollment period, which began on
- October 17th and ends on November 4th. Because all forms are being faxed in this year, it is difficult
- 21 to determine what vaccines have been selected and what providers are changing in comparison to
- 22 the previous periods. From initial data analysis, there seems to be a change from Menveo to
- 23 Menactra, and there has been little interest in switching to Hiberix.

24

- Ms. DeLeon concluded the DOH updates by saying that the Department continues to see steady
- ordering, which is monitored closely because providers have to contact the DOH to order
- 27 Meningoccoal B and has been steadily increasing.

28 29

<u>Flu Mist</u>

- 30 Chairman Marcuse then directed the Committee to the handout showing the history and
- background of LAIV, or Flumist. He noted that several Board members have expressed concern
- as to why it was not as effective as originally thought. LAIV was approved in 2003, and there are
- three to four components in the LAIV strain that is given through the nose. Flu strains change
- annually and in 2009, a pandemic strain was introduced. LAIV supposedly gave a greater cross
- protection. The data of efficacy decreased over the next three years when it became clear that
- 36 LAIV 4 was inferior to other strains and gave no protection to the H1N1 strain. LAIV 3 and 4 are
- 250 Liviv + was interior to other strains and gave no protection to the 1111v1 strain. Liviv 3 and 4 are
- 37 currently being used in Canada and Europe. Chairman Marcuse reviewed several hypotheses of
- 38 why LAIV does not work, such as the addition of the fourth influenza and interfered with viral
- 39 replication; however, there are no definite known reasons for the inefficacy of Flumist at this time.
- 40 Ms. Roberts asked if there is any new data for the ACIP's review regarding why the vaccine was
- 41 ineffective. Chairman Marcuse replied that he was not aware of any discussions regarding actual
- 42 examination of data to determine the cause.

43 44

Dr. John Dunn proceeded to discuss optimal timing of annual flu vaccine.

1 Optimal timing of Annual Flu Vaccine

John Dunn began the discussion of optimal timing of flu vaccine and noted that in the past, the 2 general rule was to avoid vaccination before October, especially for the elderly because of the 3 4 rapid decline of the vaccine-induced antibody. In 2009, the general rule became that vaccines should be administered if possible by October to decrease the likelihood of contamination. That 5 soon changed, however, and in 2010, it was recommended that flu vaccine should be administered 6 as soon as it is available and continue for the remainder of flu season. The current CDC 7 recommendation is that flu vaccination should begin after vaccine becomes available, if possible 8 9 by October, Dr. Dunn explained that the optimal time to vaccinate has changed throughout the last several years and there are many factors that affect this. For example, peak influenza activity has 10 occurred in or after January and February; yet in recent seasons, vaccine shipments have begun as 11 early as July. The Committee discussed the difficulty of serving a high volume of children in as 12 little as two months as recommended and it is necessary to vaccinate children when able in order 13 to decrease the chance of missed opportunities. 14

15 16

<u>KidsVax Updates</u>

- 17 Chairman Marcuse thanked Dr. Dunn and asked if the representatives from Crowell and Moring
- 18 (C&M) would like to give any updates regarding TRICARE's participation in universal vaccine
- purchase (UVP) states. Jim Flood, the chair of C&M's Government Affairs Group, thanked the
- 20 Committee for allowing them to participate in the meeting and gave an update on the current
- 21 legislation and 2017 plan for addressing the arrears. Mr. Flood gave an overview of the process
- 22 throughout 2015 and 2016 to get legislation in the National Defense Authorization Act (NDAA).
- The provision is in the final Senate version and C&M is confident that it will be passed in the
- NDAA, which will be most likely be passed in December. C&M is currently strategizing with KV
- and other UVP representatives regarding legislation for the arrears in 2017.

26

27 Closing

There being no further business, the meeting adjourned at approximately 1:33 p.m.



What: Vaccine Committee Meeting

Date & Time: Thursday, November 3, 2016; 12:30-1:30 p.m. PDT

Location: Alki Conference Room. Ellis, Li, & McKinstry 2025 1st Ave, PH-A Seattle, WA 98121


Conference Line: (267) 930-4000; Conference ID: 103063718#

Notice: The meeting may be recorded for the benefit of the secretary. The WVA intends to delete the recording after the minutes of the meeting are approved.

AGENDA for Vaccine Committee Meeting (in person attendance if possible)

Approx. Time 12:30-12:35 p.m.	1.	Topic/[Anticipated Action] Welcome & Introductions a. Survey of Other Topics	Presented by: E. Marcuse
12:35-1:00 p.m.	2.	Department of Health a. Flu Allocation and Ordering b. Preservative-Free Flu Vaccine c. Cell-free and recombinant Flu Vaccines d. Meningococcal B Vaccine e. HPV2 f. Current Vaccine Choice Period g. Additional Vaccine Supply Updates	S. DeLeon
1:00-1:05 p.m.	3.	Flu Mist	E. Marcuse
1:05-1:20 p.m.	4.	Optimal Timing of Annual Flu Vaccine	J. Dunn
1:20-1:25 p.m. *	5.	KidsVax Updates a. WVA Provider Communications	J. Walter
1:25-1:30 p.m. *Indicates agenda item attached Red text indicates an action item	6.	Closing	E. Marcuse

WAvaccine.org



Ensuring Universal Purchase of Childhood Vaccines in Washington The Washington Vaccine Association (WVA) and the Department of Health work together in a public/private partnership to support Washington's universal Childhood Vaccine Program. The state uses a combination of federal and state funds to make vaccine available at no cost to all children in Washington.

Removing cost as a barrier assures that all Washington children have ready access to life-saving vaccines.

Providers make this possible by including the Dosage Based Assessment (DBA) process with their claims submission. This critical step allows physicians, clinics, hospitals, and other providers to receive vaccine for all children at no cost.

It's important that provider office billing staff understand how to complete the DBA process. For your convenience, we created this Quick Guide.

Completing the DBA Process

BY MAIL

You will be filling out the Health Insurance Claim Form twice, filling it out once as the Administration Claim Form and once as the HCFA1500/DBA Form.

STEP1

Fill out the HCFA 1500 as the Administration Claim Form

Fill out HCFA 1500 Form for the administration of the vaccine, office visit, and other charges. This claim should include only the administration codes, office call or other charges.

Do not include vaccine codes and modifiers.

STEP2

Fill out HCFA 1500 as the DBA Form.

The DBA Form must include:

Box 21 Enter "Z 23"

(this is the only diagnosis required).

Box 24d Enter CPT code for the state-supplied vaccine given (Do not include modifiers)

Box 24f Enter WVA charge based on the current grid, found online at *wavaccine.org/wavaccine.nsf/pages/AssessmentGrid.html*

Box 24j Enter WVA NPI (1699092718)

Box 25 WVA TIN (27-2251833)

Boxes 31&32 Complete both areas with

the same information that is on the administration claim

Box 32a Enter Provider NPI

Box 33 Washington Vaccine Association, PO Box

94002, Seattle, WA 98124-9402

Box 33a Enter the WVA NPI (1699092718)

STEP3

Submit via Mail

Mail the Administrative Claim Form and DBA Form to the payer (health plan, insurance company, or third-party administrator) — not to the WVA.

Do not submit to WVA.

	NCE CLAIM F	E AND ICCL 09/19							
PICA	JI W OLDANI OLDANI I IL	(1000) 01112							PICA
1. MEDICARE MEDICAR		CHAMPV.		PLAN FEG BLKI		1a. INSURED'S I.D. I	UMBER		(For Program in Item 1
(Medicarde) (Medicaide 2. PATIENT'S NAME (Last Name		(Member K			(AD#)	4. INSURED'S NAME	All and Mass	a Cinct Name	on Relative to be to 1
			3. PATIENT'S B	YY M	F		. ,	.,	.,
5. PATIENT'S ADDRESS (No., St	reet)			LATIONSHIP TO		7. INSURED'S ADDE	ESS (No., 1	Street)	
CITY		STATE	Self Sp 8. RESERVED	cuse Child	Other	CITY			STATE
		O IAIL							
ZIP CODE	TELEPHONE (Include a	Area Code)				ZIP CODE		TELEPHO	NE (Include Area Code)
9 OTHER INSURED'S NAME IT	()	iddio leitiol)	TA 10 DATIENT	S CONDITION BE	DI ATED TO:	11 INSUREDS POL	rv agaus	() NIMBED
			IV. IS PATIENT						
a. OTHER INSURED'S POLICY O	OR GROUP NUMBER		s. EMPLOYMEN	NT? (Current or Pr		a. INSURED'S DATE	OF BIRTH		SEX
b. RESERVED FOR NUCC USE			b. AUTO ACCID		NO PLACE (State)	b. OTHER CLAIM ID	Designate		M F
			Do	not	NO FILE (SEM)				
c. RESERVED FOR NUCC USE			c. OTHER AGO	DEATHOU		c. INSURANCE PLAI	NAME OF	PROGRAM	NAME
d. INSURANCE PLAN NAME OR	PROGRAM NAME	0:	rt at la	YES C	oeti.	ERE ANOTH	ER HEALTI	H BENEFIT I	PLAN?
		Οt	at tn	15.2	ecn	OH VES			plete items 9, 9a, and 9d.
SIGNED	S IN HIDY ~ DDEGNA	NCV (I MD) 15	DATE			SIGNED_	LINADI E T	n woek in	CHEDENT OCCURATION
14. DATE OF CURRENT ILLNES	JAL.	QU/		MM DD	YY	FROM	NAMOTE A	y wonk in	CURRENT OCCUPATION TO
17. NAME OF REFERRING PRO	VIDER OR OTHER SOU						N DATES		O CURRENT SERVICES
10 ADDITIONAL CLAIM INFORM	SATION (Designated by 8	17b	. NPI			20 OUTSIDE LAR?			FO CHARGES
						YES [NO		
21. DIAGNOSIS OR NATURE OF	ILLNESS OR INJURY I	Relate A-L to servi	ice line below (24	E) ICD Incl.		22. RESUBMISSION CODE		ORIGINAL	REF. NO.
A.L	B. L.	. C. L.		D. L.		23. PRIOR AUTHOR	ZATION N	JMBER	
L L	J. L.	К. Ц							
24. A. DATE(S) OF SERVIC From 1 MM DD VV MM D	To PLACE OF		in Unusual Circus	ES, OR SUPPLIE Instances) MODIFIER	DIAGNOSIS POINTER	F. 8 CHARGES	G. DAYS OR UNITS	PSOT ID.	RENDERING PROVIDER ID 1
DATE OF SERVICE		PROVIDE	R CPT		a	SPROVIDER AMO	UNT	NPI	PROVIDER NPI
DATE OF SERVICE		PROVIDE	R CPT		ø	SPROVIDER AMO	UNT	NPI	PROVIDER NPI
								NPI	
		Fill.	Out	this	sec	tion			
			Jul	11113	300			NPI	
								NPI	
								NPI	
25. FEDERAL TAX I.D. NUMBER	SSN EIN	26. PATIENT'S A	ACCOUNT NO.	27. ACCEPT	ASSIGNMENT?	28. TOTAL CHARGE	29	AMOUNT F	PAID 30. Revd for NU
25. FEDERAL TAX I.D. NUMBER PROVIDER TIN 31. SIGNATURE OF PHYSICIAN		26. PATIENT'S A		27. ACCEPT Prigot.	ASSIGNMENT?	S TOTAL CHARGE S TOTAL 33. BILLING PROVID	s		PAID 30. Revel for NU

Step1: Administration Claim Form

SAMPLE DBA FORM							
		PAYER 1000 EXAMPLE STREET SMITH, MO 63857					
III MITH, MU 0395/ III MITH, MU 0395/ III MITH, MU 0395/ III MITH, MU 0395/ III MITH MITH MITH MITH MITH MITH MITH							
PPHOVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NOCC) 02/12			PICA TT				
MEDICARE MEDICAID TRICARE CHAMPV (Medicarel) (Medicaidl) ((DeCoOl) (Member A		1a. INSURED'S I.D. NUMBER 000013235	(For Program in Item 1)				
2. PATIENT'S NAME (Last Name, First Name, Middle Initial) SMITH, GRACE S.	3. PATIENT'S BIFTH DATE SEX 02 04 2011 M F	4. INSURED'S NAME (Last Name, First Name, SMITH, EDDIE	Middle Initial)				
5. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS (No., Street)					
16 OCEAN STREET	Self Spouse Child Other	16 OCEAN STREET					
WALTHAM WA	8. RESERVED FOR NUCC USE	WALTHAM	STATE WA				
ZIP CODE TELEPHONE (Include Area Code)	1	ZIP CODE TELEPHONE	E (Include Area Code)				
98374 (360) 111-0000			D) 111-0000 E				
OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)	10. IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GROUP OR FECA NU NONE	SEX SEX SEX SEX AMAGE AMA				
a. OTHER INSURED'S POLICY OR GROUP NUMBER	a. EMPLOYMENT? (Current or Previous) YES NO	a. INSURED'S DATE OF BIRTH SEX MM DD YY 05 29 1988 M					
b. RESERVED FOR NUCC USE	b. AUTO ACCIDENT? PLACE (State)	b. OTHER CLAIM ID (Designated by NUCC)	9				
c. RESERVED FOR NUCC USE	c. OTHER ACCIDENT?	c. INSURANCE PLAN NAME OR PROGRAM N	ALLE E				
C. RESERVED FOR HOLD GUL	YES NO	INSURANCE CARRIER	E I				
d. INSURANCE PLAN NAME OR PROGRAM NAME	10d. CLAIM CODES (Designated by NUCC)						
READ BACK OF FORM BEFORE COMPLETING 12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE: I surfaction the to process this claim. I also request payment of government benefits either below.	NISURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.						
SIGNED SIGNATURE ON FILE	DATE 7/30/2014	SIGNED SIGNATURE ON FIL					
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) 15.	OTHER DATE MM DD YY	16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION MM DD YY FROM TO TO					
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a	4	18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES					
DN RON EXAMPLE 178	NPI 1234567891	FROM TO 20 OUTSIDE LAR? S.CHARGES					
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)		YES NO SCHARGES					
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to serv	vice line below (24E) ICD Ind. 9	22. RESUBMISSION ORIGINAL RI	FF 100				
A. LV061 8. LV053 9 4 c. L	V0382 D. LV0489						
E F G. L	н 📖	23. PRIOR AUTHORIZATION NUMBER					
24. A. DATE(S) OF SERVICE B. C. D. PROCE	DURES, SERVICES, OR SUPPLIES E.	F. G. H. L.	J. Z				
From To PLACEOF (Expla	ain Unusual Circumstances) DIAGNOSIS PCS MODIFIER POINTER	F. G. H. L. DAY'S BOOT D. OR Family UNITS Pan QUAL	RENDERING PROVIDER ID. #				
		2/1f	24i &				
07 30 2014 07 30 2014 22 90698	24d ^	∠ 1 62 1 NPI	16990 TI				
07 30 2014 07 30 2014 22 90744	ETU	12 10 1 NPI	1699092718				
07 30 2014 07 30 2014 22 90670	С	117 83 1 NPI	PENDERING NO PROVIDER IO. 9 PROVIDER				
07 30 2014 07 30 2014 22 90680	D	70 36 1 NPI	1699092718				
	DO NOT USE MODIFIERS		1699092718 BHASICIAN O				
		NPI	38				
SEE: WWW.WAVAC	CCINE.ORG FOR LATEST PRICING	GRID	\ E				
25. FEDERAL TAX LD. NUMBER SSN EIN 25. PATIENTS A		28. TOTAL CHARGE 29. AMOUNT PA	ID 30. Revd for NUCC Use				
272251833 25 B48532	YES NO	s 261 91 s					
31. SIGNATURE OF PHYSICIAN OR SUPPLER INCLUDING DEGREES OR DEFENTIALS (I certify that the statement on the reverse apply to this art after made a part thereof.) PHYSICIAN SIGNATURE	ACILITY LOCATION INFORMATION ACILITY 3.2 NA 9834.2	33. BILLING PROVIDER INFO & PH # (88 WASHINGTON VACCINE A TPO BOX 94002 SEATTLE, WA 98124-9402	8) 928-2224 TION				
PHYSICIAN SIGNATURE	a •	.33a					

Step 2:
DBA Form

You have the option of filling out the Forms electronically (preferred) or by mail.





STEP1

Fill out the DBA Form electronically

The Form must include:

- 1. Billing provider Federal Tax ID Number
- 2. Billing provider information
- 3. Patient account number
- 4. Signature of physician or supplier
- 5. Service facility location & facility NPI
- 6. Service line and date of service
- 7. CPT Code
- 8. Charges

STEP2

Submit Electronically

Submit the Administrative Claim Form and DBA Form to the payer (health plan, insurance company, or third-party administrator) via your company clearinghouse — not to the WVA.

Do not submit to WVA.

DENIED CLAIMS

If the administrative claim is denied for incorrect demographic or eligibility information, please re-file the WVA claim with the corrections. The WVA relies on provider offices to ensure that any denied claims are re-filed correctly.

OUESTIONS?

You can find answers to many questions on the "FAQs" page at **www.wavaccine.org**.

Note for first time electronic filers

The first time you use the electronic DBA process, please notify your claim clearinghouse that you intend to submit the electronic Form using the DBA process with WVA's name, Tax ID, and NPI.

Important Numbers

WVA National Provider Identifier (NPI):

1699092718

WVA Tax Identification Number (TIN):

27-2251833

	937 Floatura in Claims Burfossian al					
	837 Electronic Claim - Professional					
			Segment/		Qualifier	
	X12N 837, Version 5010A1 Claim - Field Description	Loop	-	Qualifier	Description	Data for WVA DBA Process
1	Billing Provider Federal Tax ID Number (TIN)	2010AA	REF01	EI	for EIN	
Ī				SY	for SSN	27 2254022
	TIN	2010AA	REF02			27-2251833
2	Billing Provider Information	2010AA	NM101	85		
	Billing Provider Entity Type	2010AA	NM102	2		Washington
	Billing Organizational Name	2010AA	NM103			Vaccine Association
	Identification Code Type	2010AA	NM108	XX	NPI	
	National Provider Identifier (NPI)	2010AA	NM109			1699092718
	Billing Provider Address	2010AA	N3			leave blank
	Billing Provider Address - Line 1 Billing Provider Address - Line 2	2010AA 2010AA	N301 N302			Marketplace Tower PH-A 2025 First Ave
	Billing Provider City, State, ZIP Code	ZUIUAA	14302			LOLD I IISTAVC
	City	2010AA	N401			Seattle
	State	2010AA	N402			WA
	Zip Code	2010AA	N403			981213125
						Washington
	Pay-To Address Name	2010AB	NM101	87		Vaccine Association
	Pay-to Entity Type	2010AB	NM102	2		
	Pay-To Address	2010AB	N3			
	Pay-To Address - Line 1	2010AB	N301			PO Box 94002
	Pay-To Address - Line 2	2010AB	N302			1000034002
	Pay-To City, State, ZIP Code		N4			
	City	2010AB	N401			Seattle
	State	2010AB	N402			WA
	Zip Code	2010AB	N403			981249402
3	Patient Account Number	2300	CLM01			
	Total Charge	2300	CLM02			Total Charge Amount
4	Rendering Provider Name	2310B	NM1	02		Devide des
_	Rendering Provider Name	2310B 2310B	NM102	82		Rendering Provider Name
		23100	NM103			Rendering Provider Name
F	Service Facility Location Information	2310C				
J	Service Facility Identifier	2310C	NM101	77	Location	
						Office Address of
				FA	Facility	Service Facility
	Service Facility Type	2310C	NM102	2		
	Non-Person Name, or Person Last Name	2310C	NM103			
C	Service Line, Service Date(s)	2400	DTP01	472		
0	Service From - To Dates	2400	DTP02	RD8		
	Formatas: CCYYMMDD-CCYYMMDD	2400	DTP03			
	Procedures Services Supplies		CV/1			
7	Procedures, Services, Supplies Product/Service ID	2400	SV1	ЦС		
	Procedure - CPT/HCPCS Code	2400	SV101-1 SV101-2	HC		
		2400	3 4 1 0 1 - 2			
8	Line Item \$ Charge Amount	2400	SV102			



You make the program work!

When you use the DBA process, it allows the WVA to collect the necessary assessments from insurance carriers and third party administrators.

With your help, Washington can continue to provide vaccines to protect all children in our state.

Stay Connected

For more information, visit **www.wavaccine.org** and sign up for email alerts.

info@wavaccine.org Ph. 888-928-2224 Fax. 888-928-2242

History of LAIV Relative to Circulating Strains

• Aug 2003

LAIV3 approved by FDA

Apr 2009

A/H1N1pdm2009 circulated in United States

• Feb 2012

LAIV4 approved by FDA

- 2013-14 influenza season
- 2014-15 influenza season

"When immediately available, LAIV should be used for healthy children aged 2 through 8 years who have no contraindications."

2015-16 influenza season

"No preference is expressed for LAIV or IIV for any person aged 2 through 49 years for whom either vaccine is appropriate."

2016-17 influenza season

"In light of the evidence for poor effectiveness of LAIV in the U.S. over the last 3 influenza seasons..., for the 2016-17 season, ACIP makes the interim recommendation that LAIV should not be used"

Possible Explanations Why VE of LAIV Has Been Low for 3 Seasons

- Vaccine virus interference in quadrivalent vaccine
- Limited thermostability of A/H1N1pdm09 LAIV strain
- Pre-existing influenza immunity interferes with vaccine strain replication
- Reduced replication of A/H1N1pdm09 LAIV strain in human respiratory cells

OPTIMAL TIMING OF ANNUAL FLU VACCINE

WHERE WE'VE BEEN ...

- Initial concern about timing pertained to vaccination of the elderly
 - o From at least the 1990s until the current decade, ACIP cautioned that vaccine-induced antibody to Influenza declines more rapidly in the elderly than in young adults
 - "Vaccination before October should therefore should be avoided"
- Later evidence that antibody level at a point several months after vaccination does not necessarily correlate with clinical vaccine effectiveness
 - o Review showed no compelling evidence of quicker decline of vaccine-induced antibody in the elderly compared with young adults
 - No evidence that seroprotection was lost at 4 months if it was initially achieved after immunization.
 - Lack of evidence for late-season outbreaks among vaccinated persons that can be attributed to waning immunity
- 2009: "In general, health-care providers should begin offering vaccination soon after vaccine becomes available and if possible by October."
 - o Although peak Influenza activity generally does not occur until January-March, flu season can occasionally begin as early as October.
 - Controlling spread of Influenza requires having as many people as possible immunized before the virus appears in the community (this will limit the number of people that can act as vectors for transmission to others).
- By 2010: "Vaccination efforts should begin as soon as vaccine is available and continue through the influenza season, which typically extends through April."
 - o H1N1 Pandemic demonstrated shortfalls in earlier approach, and more robust surveillance demonstrated that flu viruses circulate at some level year-round.
 - Concern that when an opportunity-to-vaccinate is deferred until later in the season, it might be missed entirely (e.g. because a given individual may not show up in the office again for six months)
 - Concern that process problems associated with vaccinating large numbers in a limited time frame (e.g. long wait times, inadequate staffing, vaccine shortages) may prevent optimal vaccination of all of those for whom it is necessary.
- NOW: Some shift back ...

WHERE WE ARE ...

- Current CDC recommendation: "Flu vaccination should begin soon after vaccine becomes available, if possible by October. However, as long as flu viruses are circulating, vaccination should continue to be offered throughout the flu season, even in January or later."
- GOAL: Ensure the vaccination of as many persons as possible before influenza activity in the community begins
 - o In any given season, the optimal time to vaccinate cannot be predicted precisely
 - May be as early as October; however ...
 - o In 74% of influenza seasons since 1982, peak influenza activity occurred in or after January (February or later in 59% of seasons)
- In recent seasons, initial shipments of vaccine have arrived as early as July.
 - o Again raises questions related to the ideal time to begin vaccination
 - Newer observational studies (2011-2015) report decreased vaccine protection within a single season (especially against A-H3N2), and a more-pronounced decline in protection among older adults
 - Castilla 2013: Decline in vaccine effectiveness from 61% in 0-100 days post-vaccination > 42% 100-119 days out > -35% (95% CI = -211-41) after 120 days. Primarily affected persons ≥65 years old OR for influenza in this group was 20.81 (95% CI = 2.14-202.71; p = 0.009) for persons vaccinated >120 days before diagnosis compared to those vaccinated <100 days before diagnosis.</p>
 - Pebody 2013: Vaccine effectiveness against A(H3N2) = 53% if vaccinated <3 months ago vs 12% if vaccinated ≥3 months ago.</p>
 - Belongia 2015: Modest but significant increase in the OR for A(H3N2) influenza with time-since-vaccination among young children age 2 & adults age 75. OR increases by 1.2 every 14 days after vaccination for children, & by 1.3 for each 14-day interval for adults aged 75 years.
 - This has not been observed consistently across age groups and across all flu seasons
 - Observed decline in protection could be attributable to other factors, e.g. increased circulation of antigenically drifted variants over the course of the influenza season.
- UPSHOT: "Inconsistent evidence for intraseason waning of influenza vaccine protection makes drawing conclusions difficult, and further evaluation of this effect in larger studies and different seasons is needed."
 - Delaying vaccination until later in the season might result in greater immunity later in the season
 - O Deferral might also result in missed opportunities to vaccinate and difficulties in vaccinating a population within a more constrained time period.
 - GUIDANCE: "Community vaccination programs should balance maximizing likelihood of persistence of vaccine-induced protection through the season with avoiding missed opportunities to vaccinate or vaccinating after onset of influenza circulation occurs."